J&J Rides Consumer Health ‘Growth Annuity’ As Rx, Device Divisions Slow
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson’s second-quarter U.S. OTC sales jumped nearly 16% on the return of recalled brands and Worldwide Group Chairman Peterson says J&J expects the consumer business to grow “increasingly” more robust.
You may also be interested in...
J&J Baby Care Launches Crucial To Second-Half Consumer Business Results
Baby care products sales were a drag on J&J's consumer sector, falling at a reported 7.7% to $456m. US sales particularly were off, down reported21.2% to $89m, and international results were off 3.7% to $367m. Worldwide beauty sales were up a reported 3.1% to $1.11bn, but US sales were down 1.8% to $637m.